Skip to main content
StemRIM Inc. logo

StemRIM Inc. — Investor Relations & Filings

Ticker · 4599 ISIN · JP3399690001 T Professional, scientific and technical activities
Open in API
Filings indexed 65 across all filing types
Latest filing 2024-07-26 Regulatory Filings
Country JP Japan
Listing T 4599

About StemRIM Inc.

https://stemrim.com/english/

StemRIM Inc. is a biotechnology company developing a next-generation category of regenerative medicine called “Regeneration-Inducing Medicine™”. This innovative approach aims to treat intractable diseases and injuries by maximizing the body's innate tissue repair capabilities. The core mechanism of action involves mobilizing a patient's own endogenous stem cells to damaged tissues to induce functional regeneration, a method distinct from conventional cell-therapy. The company's research and development focuses on creating new drugs based on this novel mechanism, with applications including gene therapy for rare skin diseases such as dystrophic epidermolysis bullosa.

Recent filings

Filing Released Lang Actions
臨時報告書
Regulatory Filings Classification · 1% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is submitted to the Kinki Local Finance Bureau. Section 1 explicitly states the reason for filing: to report the resolution made by the Board of Directors on July 25, 2024, regarding the issuance of stock options (new share warrants) to directors, pursuant to Article 24-5(4) of the Financial Instruments and Exchange Act. The content details the specifics of the stock option issuance (number of warrants, exercise price, vesting conditions, etc.). This type of filing, reporting a significant corporate action like stock option issuance outside of routine periodic reports, is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP). Since the core purpose is the official disclosure of a specific corporate resolution mandated by timely disclosure rules, and it doesn't fit neatly into the other specific categories (like 10-K, ER, or DIV), RNS is the most appropriate general regulatory fallback. The document length (4931 chars) is substantial enough that it is the report itself, not just an announcement of a report, but the content is a specific regulatory disclosure. Given the options, 'RNS' (Regulatory Filings - general regulatory announcements and fallback) is the best fit for a Japanese '臨時報告書' detailing a stock option grant.
2024-07-26 Japanese
臨時報告書
Capital/Financing Update Classification · 1% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is filed with the Kinki Local Finance Bureau. The filing reason explicitly states that the company resolved to issue stock options (新株予約権) to employees based on the Companies Act and is submitting this report under the Financial Instruments and Exchange Act (Article 24-5, Paragraph 4) and related regulations. The content details the issuance terms, including the number of options, exercise price, and vesting conditions. This type of mandatory disclosure regarding the issuance of stock options falls under corporate financing/capital structure changes, but the specific Japanese regulatory filing type for this event is often classified as a general timely disclosure or a specific capital event. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate category as it directly relates to the issuance of new equity instruments (stock options) for employee compensation, which is a financing/capital structure activity. It is not a standard 10-K, AR, or ER. Since it is a detailed report of the resolution rather than just an announcement of the report's availability, RPA/RNS is less precise than CAP.
2024-07-26 Japanese
臨時報告書
Share Issue/Capital Change Classification · 1% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and explicitly states in Section 1 that it is being filed pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act because resolutions were passed at an Extraordinary General Meeting of Shareholders held on July 24, 2024. Section 2 details the resolution, which was a capital reduction (減資). This type of filing, reporting the results of a shareholder meeting (especially an extraordinary one concerning major corporate actions like capital changes), aligns best with reporting the results of a general meeting. While it reports on the results of a vote, the primary context is the official disclosure of the outcome of a shareholder meeting, which is often captured under general regulatory filings or specific voting result declarations. Given the options, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most specific fit for reporting the outcome of resolutions passed at a shareholder meeting. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard proxy statement (PSI). Since it reports the definitive results of a vote, DVA is appropriate.
2024-07-25 Japanese
確認書
Report Publication Announcement Classification · 1% confidence The document text contains the title "第３四半期報告書" (Third Quarter Report) and specifies a reporting period: "第19期第３四半期（自2024年２月１日 至2024年４月30日）". It also includes a confirmation statement by the CEO regarding the appropriateness of the quarterly report's contents, filed with the Kinki Local Finance Bureau. This structure strongly indicates a comprehensive financial report covering a period shorter than a year, which aligns with the definition of an Interim / Quarterly Report (IR). Although it is a confirmation document related to the report, the core subject matter is the quarterly financial reporting period itself, making 'IR' a more specific classification than a general 'RPA' or 'RNS', especially given the explicit mention of the 'Quarterly Report' content being confirmed.
2024-06-13 Japanese
四半期報告書－第19期第3四半期(2024/02/01－2024/04/30)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (四半期報告書) for StemRIM Inc., covering the third quarter of the 19th fiscal period (February 1, 2024, to April 30, 2024). It contains detailed financial statements, management analysis (MDA), and corporate information as required by the Financial Instruments and Exchange Act of Japan. Since it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. Q3 2024
2024-06-13 Japanese
四半期報告書－第19期第2四半期(2023/11/01－2024/01/31)
Interim / Quarterly Report Classification · 1% confidence The document is a '四半期報告書' (Quarterly Report) filed by StemRIM Inc. with the Kinki Local Finance Bureau in Japan. It contains detailed financial statements, management analysis (MDA), and operational updates for the second quarter of the 19th fiscal period (covering November 1, 2023, to January 31, 2024). As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report (IR). Q2 19
2024-03-14 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.